OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Diffuse Large B-Cell Lymphoma Recurrent reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,120 reports · 51 co-occurring drugs

As of the last recalculation, Diffuse Large B-Cell Lymphoma Recurrent appears in 2,120 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is POLATUZUMAB VEDOTIN (PRR 441.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Polatuzumab Vedotin364441.9459.1
Doxorubicin1,127264.0267.4
Bendamustine Hcl293215.1219.2
Rituximab1,437205.1206.5
Cyclophosphamide Injection, Solution1,247166.5167.7
Cyclophosphamide1,247166.5167.7
Cyclophosphamide For Injection1,247166.5167.7
Ifosfamide283149.1151.1
Doxorubicin Hydrochloride363131.5133.0
Vincristine Sulfate323127.5128.9
Axicabtagene Ciloleucel103107.7108.8
Cytarabine481101.4102.2
Gemcitabine31391.392.1
Gemcitabine Hydrochloride37383.584.1
Etoposide46479.079.5
Bendamustine Hydrochloride7765.565.9
Cisplatin36855.856.0
Melphalan8236.836.9
Oxaliplatin23835.435.5
Melphalan Hydrochloride8635.135.2
Prednisone95733.233.3
Obinutuzumab5332.432.5
Fludarabine Phosphate11730.931.0
Bleomycin Sulfate2827.027.0
Carboplatin27624.424.4
Dexamethasone 1.5 Mg52923.323.3
Dexamethasone52923.023.0
Prednisolone31720.120.1
Prednisolone Oral31720.120.1
Prednisolone Oral Solution31720.120.1
Mesna1618.818.8
Mesna Injection1517.918.0
Temozolomide2913.713.7
Entecavir1311.011.0
Ibrutinib8610.910.9
Thiotepa1010.310.3
Dexamethasone Sodium Phosphate98.78.7
Filgrastim318.28.2
Methotrexate2907.77.7
Selinexor66.86.8
Piperacillin Sodium,Tazobactam Sodium166.06.0
Brentuximab Vedotin65.85.8
Posaconazole Delayed-Release65.45.4
Venetoclax325.25.2
Pertuzumab134.74.7
Blinatumomab54.74.7
Micafungin Sodium44.64.6
Sofosbuvir84.04.0
Lenalidomide1593.93.9
Acalabrutinib43.23.2
Pegfilgrastim202.02.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.